SAS Output

23-JAN-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 550 129 0 0 0 BREAST
        9383 550 129 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 192 53 1 0 0  
      3 Endocrine Therapy Alone 2536 198 52 1 0 0  
        5083 390 105 2 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 734 201 87 44 12 5 BREAST
      2 Blinded drug + Endocrine 746 216 104 45 17 3  
        1480 417 191 89 29 8  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 4 3 3 1 0 0 SURV
      2 Randomization Non-surgical M 5 5 4 4 0 0  
      3 Patient Choice Surgery 37 18 8 1 0 0  
      4 Patient Choice Non-surgical M 88 49 27 11 4 2  
        134 75 42 17 4 2  
 
S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 130 49 27 13 4 1 LUNG
      2 Nivolumab 126 47 18 6 1 0  
        256 96 45 19 5 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 389 325 130 59 25 9 CCD
      2 Site randomized: Control 261 256 132 64 18 3  
      3 SiteRand Int Risk: CSF 392 372 240 127 45 14  
      4 SiteRand Int Risk: No CSF 282 275 182 77 13 2  
        1324 1228 684 327 101 28  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 164 146 87 43 15 5 CCD
        164 146 87 43 15 5  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 141 139 92 49 15 3 BREAST
        141 139 92 49 15 3  
 
  2 Y 2 Observation 62 62 40 23 4 1  
      3 MK-3475 (Pembrolizumab) 58 58 39 18 7 1  
        120 120 79 41 11 2  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 4 4 4 4 1 0 SURV
        4 4 4 4 1 0  
 
  2 Y 1 Carvedilol 1 1 1 1 0 0  
      2 No intervention 1 1 1 1 0 0  
      3 Observation 1 1 1 1 0 0  
        3 3 3 3 0 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 22 22 17 7 2 1 GU
      2 Tokyo-172 BCG 21 21 16 8 2 1  
      3 Prime + Tokyo-172 BCG 21 21 17 9 2 1  
        64 64 50 24 6 3  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 442 127 62 34 6 2 PREV
        442 127 62 34 6 2  
 
  1 Y 1 Blinded drug 50 18 8 5 1 1  
      2 Blinded drug 36 6 0 0 0 0  
      3 Blinded drug 35 4 0 0 0 0  
      4 Blinded drug 57 28 16 9 4 0  
        178 56 24 14 5 1